TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07484204: An Open-label, Multicenter Study to Determine the Pharmacokinetics, Safety, and Tolerability of AX251 Long-Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

Sponsor: Anxo Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,144,880

Rescue Site Savings

+$3,403,536

Unlock Full NCT07484204 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07484204 Rescue Dossier →